

Letter to the Editor

Dear Editor,



It is indeed a pleasure to see the continued expansion and progression of *Alzheimer's & Dementia: Diagnosis, Assessment and Disease Monitoring*, over the last 3 years. The editors and the editorial board are to be commended in the selection and publication of many important manuscripts that continue to advance the field's understanding of Alzheimer's and dementia, arguably perhaps one of the most important global public health problems.

As many readers appreciate, the Journal's title developed out of the early work by the Alzheimer's Association and the National Institute on Aging (NIA) to launch the International Alzheimer's Disease Research Portfolio (IADRP) project. The effort is credited with capturing the evolving nature of Alzheimer's disease research as funded by several different international sponsors. In addition, the project aimed to identify "opportunities for possible coordination of support for Alzheimer's disease research" and "funding gaps as well as areas of overlap within and across domestic and international funding agencies". To help aid this effort in identifying important gaps, the Journal has played an important supporting role.

The *Alzheimer's & Dementia* journal family, which also includes *Alzheimer's & Dementia* and *Alzheimer's & Dementia: Translational Research & Clinical Interventions*, is focused on several pressing challenges confronting the field. These include the inadequacy of current treatments to alleviate the symptoms of the disease. Also, the difficulty in developing novel interventions to detect [1–57], delay [58–69], or halt disease progression continues to be an important hurdle. The well-recognized public health and economic imperative [70–83] posed by the disease continues to be an important motivator to communicate new knowledge across multiple disciplines that will help increase the likelihood of unlocking the complexity of neurodegeneration [84–90] associated with many dementing illnesses.

The Editors within the journal family are challenging authors and reviewers to calibrate articles that better

assimilate *what is known* with *emerging evidence*. The goal is to promote discussions on new approaches about the biology of dementing illnesses. To this extent, the Journal has successfully encouraged authors to use a variety of techniques for data collection, modeling, and analysis.

Sincerely,

Editorial Office, *Alzheimer's & Dementia*

Ara S. Khachaturian*

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

Alzheimer's & Dementia: Translational Research & Clinical Interventions

Alzheimer's & Dementia: Diagnosis, Assessment and Disease Monitoring

References

- [1] Mayeda ER, Glymour MM, Quesenberry CP, Johnson JK, Perez-Stable EJ, Whitmer RA. Survival after dementia diagnosis in five racial/ethnic groups. *Alzheimer's Dement* 2017;13:761–9.
- [2] Burggren AC, Mahmood Z, Harrison TM, Siddarth P, Miller KJ, Small GW, et al. Hippocampal thinning linked to longer TOMM40 poly-T variant lengths in the absence of the APOE ε4 variant. *Alzheimer's Dement* 2017;13:739–48.
- [3] Mirza SS, Ikram MA, Bos D, Mihaescu R, Hofman A, Tiemeier H. Mild cognitive impairment and risk of depression and anxiety: A population-based study. *Alzheimer's Dement* 2017;13:130–9.
- [4] Rasmussen KL, Tybjaerg-Hansen A, Nordestgaard BoG, Frikke-Schmidt R. Plasma apolipoprotein E levels and risk of dementia-A Mendelian randomization study of 106,562 individuals. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.05.006>. [Epub ahead of print].
- [5] Osler M, Christensen GT, Garde E, Mortensen EL, Christensen K. Cognitive ability in young adulthood and risk of dementia in a cohort of Danish men, brothers, and twins. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.04.003>. [Epub ahead of print].
- [6] Tolppanen A-M, Taipale H, Hartikainen S. Head or brain injuries and Alzheimer's disease: A nested case-control register study. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.04.010>. [Epub ahead of print].
- [7] Karageorgiou E, Vessel KA. Brain rhythm attractor breakdown in Alzheimer's disease: Functional and pathologic implications. *Alzheimer's Dement* 2017;13:1054–67.
- [8] Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, et al. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. *Alzheimer's Dement* 2017;13:841–9.
- [9] Capozzo R, Sassi C, Hammer MB, Arcuti S, Zecca C, Barulli MR, et al. Clinical and genetic analyses of familial and sporadic

*Corresponding author. Tel.: 301-309-6730; Fax: (844) 309-6730.

E-mail address: adj_xed@kra.net

URL: <http://www.alzheimersanddementia.org>, <http://adj.edmgr.com>

- frontotemporal dementia patients in Southern Italy. *Alzheimer's Dement* 2017;13:858–69.
- [10] Brenowitz WD, Hubbard RA, Keene CD, Hawes SE, Longstreth WT, Woltjer RL, et al. Mixed neuropathologies and estimated rates of clinical progression in a large autopsy sample. *Alzheimer's Dement* 2017; 13:654–62.
- [11] Lam B, Khan A, Keith J, Rogaeva E, Bilbao J, St. George-Hyslop P, et al. Characterizing familial corticobasal syndrome due to Alzheimer's disease pathology and PSEN1 mutations. *Alzheimer's Dement* 2017;13:520–30.
- [12] Leeuwis AE, Benedictus MR, Kuijter JPA, Binnewijzend MAA, Hooghiemstra AM, Verfaillie SCJ, et al. Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer's disease. *Alzheimer's Dement* 2017;13:531–40.
- [13] Jaraj D, Wikkello C, Rabiei K, Marlow T, Jensen C, Ostling S, et al. Mortality and risk of dementia in normal-pressure hydrocephalus: A population study. *Alzheimer's Dement* 2017;13:850–7.
- [14] Handels RLH, Vos SJB, Kramerberger MG, Jelic V, Blennow K, van Buchem M, et al. Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. *Alzheimer's Dement* 2017;13:903–12.
- [15] Toledo JB, Arnold M, Kastenmuller G, Chang R, Baillie RA, Han X, et al. Metabolic network failures in Alzheimer's disease: A biochemical road map. *Alzheimer's Dement* 2017;13:965–84.
- [16] Fardo DW, Gibbons LE, Mukherjee S, Glymour MM, McCormick W, McCurry SM, et al. Impact of home visit capacity on genetic association studies of late-onset Alzheimer's disease. *Alzheimer's Dement* 2017;13:933–9.
- [17] Farina N, Page TE, Daley S, Brown A, Bowling A, Basset T, et al. Factors associated with the quality of life of family carers of people with dementia: A systematic review. *Alzheimer's Dement* 2017;13:572–81.
- [18] Then FS, Luck T, Hesser K, Ernst A, Posselt T, Wiese B, et al. Which types of mental work demands may be associated with reduced risk of dementia? *Alzheimer's Dement* 2017;13:431–40.
- [19] Drachman DA, Smith TW, Alkamachi B, Kane K. Microvascular changes in Down syndrome with Alzheimer-type pathology: Insights into a potential vascular mechanism for Down syndrome and Alzheimer's disease. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.05.003>. [Epub ahead of print].
- [20] Burns JM, Johnson DK, Liebmann EP, Bothwell RJ, Morris JK, Vidoni ED. Safety of disclosing amyloid status in cognitively normal older adults. *Alzheimer's Dement* 2017;13:1024–30.
- [21] Knopman D, Alford E, Tate K, Long M, Khachaturian AS. Patients come from populations and populations contain patients. A two-stage scientific and ethics review: The next adaptation for single institutional review boards. *Alzheimer's Dement* 2017;13:940–6.
- [22] Willette AA, Webb JL, Lutz MW, Bendlin BB, Wennberg AM, Oh JM, et al. Family history and TOMM40 *523 interactive associations with memory in middle-aged and Alzheimer's disease cohorts. *Alzheimer's Dement* 2017;13:1217–25.
- [23] Yu L, Lutz MW, Farfel JM, Wilson RS, Burns DK, Saunders AM, et al. Neuropathologic features of TOMM40 *523 variant on late-life cognitive decline. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.05.002>. [Epub ahead of print].
- [24] Mukherjee S, Russell JC, Carr DT, Burgess JD, Allen M, Serie DJ, et al. Systems biology approach to late-onset Alzheimer's disease genome-wide association study identifies novel candidate genes validated using brain expression data and *Caenorhabditis elegans* experiments. *Alzheimer's Dement* 2017;13:1133–42.
- [25] Tagliafierro L, Glenn O-C, Zamora ME, Beach TG, Woltjer RL, Lutz MW, et al. Genetic analysis of α -synuclein 3' untranslated region and its corresponding microRNAs in relation to Parkinson's compared to dementia with Lewy bodies. *Alzheimer's Dement* 2017;13:1237–50.
- [26] Felsky D, Xu J, Chibnik LB, Schneider JA, Knight J, Kennedy JL, et al. Genetic epistasis regulates amyloid deposition in resilient aging. *Alzheimer's Dement* 2017;13:1107–16.
- [27] Verghese J, Lipton R, Ayers E. Spatial navigation and risk of cognitive impairment: A prospective cohort study. *Alzheimer's Dement* 2017; 13:985–92.
- [28] Illan-Gala I, Vilaplana E, Pegueroles J, Montal V, Alcolea D, Blesa R, et al. The pitfalls of biomarker-based classification schemes. *Alzheimer's Dement* 2017;13:1072–4.
- [29] Czaja S, Gold M, Bain LJ, Hendrix JA, Carrillo MC. Potential roles of digital technologies in clinical trials. *Alzheimer's Dement* 2017; 13:1075–6.
- [30] Roalf DR, Moore TM, Mechanic-Hamilton D, Wolk DA, Arnold SE, Weintraub DA, et al. Bridging cognitive screening tests in neurologic disorders: A crosswalk between the short Montreal Cognitive Assessment and Mini-Mental State Examination. *Alzheimer's Dement* 2017; 13:947–52.
- [31] Wolf D, Bocchetta M, Boccardi M, Bocchetta M, Preboske GM, Boccardi M, et al. Reference standard space hippocampus labels according to the European Alzheimer's Disease Consortium–Alzheimer's Disease Neuroimaging Initiative harmonized protocol: Utility in automated volumetry. *Alzheimer's Dement* 2017; 13:893–902.
- [32] Grill JD, Cox CG, Kremen S, Mendez MF, Teng E, Shapira J, Ringman JM, Apostolova LG. Patient and caregiver reactions to clinical amyloid imaging. *Alzheimer's Dement* 2017;13:924–32.
- [33] Wong MW, Braidy N, Poljak A, Pickford R, Thambisetty M, Sachdev PS. Dysregulation of lipids in Alzheimer's disease and their role as potential biomarkers. *Alzheimer's Dement* 2017;13:810–27.
- [34] Jia J, Gauthier S, Pallotta S, Ji Y, Wei W, Xiao S, et al. Consensus-based recommendations for the management of rapid cognitive decline due to Alzheimer's disease. *Alzheimer's Dement* 2017;13:592–7.
- [35] Mapstone M, Cheema AK, Zhong X, Fiandaca MS, Federoff HJ. Biomarker validation: Methods and matrix matter. *Alzheimer's Dement* 2017;13:592–7.
- [36] Thambisetty M, Casanova R, Varma S, Legido Quigley C. Peril beyond the winner's curse: A small sample size is the bane of biomarker discovery. *Alzheimer's Dement* 2017;13:606–7.
- [37] Ni R, Gillberg P-G, Bogdanovic N, Viitanen M, Myllykangas L, Nennesmo I, et al. Amyloid tracers binding sites in autosomal dominant and sporadic Alzheimer's disease. *Alzheimer's Dement* 2017; 13:419–30.
- [38] Wang R, Fratiglioni L, Kalpouzos G, Lovden M, Laukka EJ, Bronge L, et al. Mixed brain lesions mediate the association between cardiovascular risk burden and cognitive decline in old age: A population-based study. *Alzheimer's Dement* 2017;13:247–56.
- [39] Weintraub S, Randolph C, Bain L, Hendrix JA, Carrillo MC. Is cognitive decline measurable in preclinical Alzheimer's disease? *Alzheimer's Dement* 2017;13:322–3.
- [40] Rockwood K, Howlett SE, Hoffman D, Schindler R, Mitnitski A. Clinical meaningfulness of Alzheimer's Disease Assessment Scale-Cognitive subscale change in relation to goal attainment in patients on cholinesterase inhibitors. *Alzheimer's Dement* 2017; 13:1098–106.
- [41] Kaniyappan S, Chandupatla RR, Mandelkow E-M, Mandelkow E. Extracellular low-n oligomers of tau cause selective synaptotoxicity without affecting cell viability. *Alzheimer's Dement* 2017; 13:1270–91.
- [42] Kielb S, Rogalski E, Weintraub S, Rademaker A. Objective features of subjective cognitive decline in a United States national database. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.04.008>. [Epub ahead of print].
- [43] Hansson O, Palmqvist S, Ljung H, Cronberg T, van Westen D, Smith R. Cerebral hypoperfusion is not associated with an increase in amyloid β pathology in middle-aged or elderly people. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.06.2265>. [Epub ahead of print].
- [44] Sepulcre J, Sabuncu MR, Li Q, El Fakhri G, Sperling R, Johnson KA. Tau and amyloid- β proteins distinctively associate to functional

- network changes in the aging brain. *Alzheimer's Dement* 2017; 13:1261–9.
- [45] Power MC, Rawlings A, Sharrett AR, Bandeen-Roche K, Coresh J, Ballantyne CM, et al., Association of midlife lipids with 20-year cognitive change: A cohort study. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.07.757>. [Epub ahead of print].
- [46] Jefferson-George KS, Wolk DA, Lee EB, McMillan CT. Cognitive decline associated with pathological burden in primary age-related tauopathy. *Alzheimer's Dement* 2017; 13:1048–53.
- [47] Sposato LA, Ruiz Vargas E, Riccio PM, Toledo JB, Trojanowski JQ, Kukull WA, et al. Milder Alzheimer's disease pathology in heart failure and atrial fibrillation. *Alzheimer's Dement* 2017; 13:770–7.
- [48] Llorens F, Kruse N, Schmitz M, Gotzmann N, Golanska E, Thune K, et al. Evaluation of α -synuclein as a novel cerebrospinal fluid biomarker in different forms of prion diseases. *Alzheimer's Dement* 2017; 13:710–9.
- [49] Caceres A, Vargas JE, Gonzalez JR. APOE and MS4A6A interact with GnRH signaling in Alzheimer's disease: Enrichment of epistatic effects. *Alzheimer's Dement* 2017; 13:493–7.
- [50] Carmona-Iragui M, Balasa M, Benejam B, Alcolea D, Fernandez S, Videla L, et al. Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer's disease. *Alzheimer's Dement* 2017; 13:1251–60.
- [51] Schindler SE, Sutphen CL, Teunissen C, McCue LM, Morris JC, Holtzman DM, et al. Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.06.2264>. [Epub ahead of print].
- [52] Scheltens NME, Tijms BM, Koene T, Barkhof F, Teunissen CE, Wolfsgruber S, et al. Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts. *Alzheimer's Dement* 2017; 13:1226–36.
- [53] Chouraki V, Preis SR, Yang Q, Beiser A, Li S, Larson MG, et al. Association of amine biomarkers with incident dementia and Alzheimer's disease in the Framingham Study. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.04.009>. [Epub ahead of print].
- [54] Ritchie K, Carriere I, Su L, O'Brien JT, Lovestone S, Wells K, et al. The midlife cognitive profiles of adults at high risk of late-onset Alzheimer's disease: The PREVENT study. *Alzheimer's Dement* 2017; 13:1089–97.
- [55] Taylor ANW, Kambeitz-Ilankovic L, Gesierich B, Simon-Vermot L, Franzmeier N, Araque Caballero MA, et al. Tract-specific white matter hyperintensities disrupt neural network function in Alzheimer's disease. *Alzheimer's Dement* 2017; 13:225–35.
- [56] Fleisher AS, Joshi AD, Sundell KL, Chen Y-F, Kollack-Walker S, Lu M, et al. Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials. *Alzheimer's Dement* 2017; 13:1117–24.
- [57] Kinnunen KM, Cash DM, Poole T, Frost C, Benzinger TLS, Ahsan RL, et al. Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial MRI study. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.06.2268>. [Epub ahead of print].
- [58] Pase MP, Himali JJ, Jacques PF, DeCarli C, Satizabal CL, Aparicio H, et al. Sugary beverage intake and preclinical Alzheimer's disease in the community. *Alzheimer's Dement* 2017; 13:955–64.
- [59] Hendrie HC, Zheng M, Li W, Lane K, Ambuehl R, Purnell C, et al. Glucose level decline precedes dementia in elderly African Americans with diabetes. *Alzheimer's Dement* 2017; 13:111–8.
- [60] Hayden KM, Beavers DP, Steck SE, Hebert JR, Tabung FK, Shivappa N, et al. The association between an inflammatory diet and global cognitive function and incident dementia in older women: The Women's Health Initiative Memory Study. *Alzheimer's Dement* 2017; 13:1187–96.
- [61] Fearnt C, Helmer C, Merle B, Herrmann FR, Annweiler C, Dartigues J-F, et al. Associations of lower vitamin D concentrations with cognitive decline and long-term risk of dementia and Alzheimer's disease in older adults. *Alzheimer's Dement* 2017; 13:1207–16.
- [62] Amadiou C, Lefevre-Arbogast S, Delcourt C, Dartigues J-F, Helmer C, Fearnt C, et al. Nutrient biomarker patterns and long-term risk of dementia in older adults. *Alzheimer's Dement* 2017; 13:1125–32.
- [63] Shih I-F, Paul K, Haan M, Yu Y, Ritz B. Physical activity modifies the influence of apolipoprotein E ϵ 4 allele and type 2 diabetes on dementia and cognitive impairment among older Mexican Americans. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.05.005>. [Epub ahead of print].
- [64] Crane A, Brubaker WD, Johansson JU, Trigunaitte A, Ceballos J, Bradt B, et al. Peripheral complement interactions with amyloid β peptide in Alzheimer's disease: 2. Relationship to A β immunotherapy. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.04.015>. [Epub ahead of print].
- [65] Brown BM, Sohrabi HR, Taddei K, Gardener SL, Rainey-Smith SR, Peiffer JJ, et al. Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease. *Alzheimer's Dement* 2017; 13:1197–206.
- [66] Stern Y, Gu Y, Cosentino S, Azar M, Lawless S, Tatarina O. The Predictors study: Development and baseline characteristics of the Predictors 3 cohort. *Alzheimer's Dement* 2017; 13:20–7.
- [67] Singh-Manoux A, Dugravot A, Shipley M, Brunner EJ, Elbaz A, Sabia S, et al. Obesity trajectories and risk of dementia: 28 years of follow-up in the Whitehall II Study. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.06.2637>. [Epub ahead of print].
- [68] Flatt JD, Gilsanz P, Quesenberry CP, Albers KB, Whitmer RA. Post-traumatic stress disorder and risk of dementia among members of a health care delivery system. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.04.014>. [Epub ahead of print].
- [69] Li J, Ogrodnik M, Devine S, Auerbach S, Wolf PA, Au R. Practical risk score for 5-, 10-, and 20-year prediction of dementia in elderly persons: Framingham Heart Study. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.04.013> [Epub ahead of print].
- [70] Dodge HH, Woltjer R, Kaye JA, Lyons D-E, Mattek N, Silbert LC, et al. Risk of incident clinical diagnosis of Alzheimer's disease–type dementia attributable to pathology-confirmed vascular disease. *Alzheimer's Dement* 2017; 13:613–23.
- [71] Phung KTT, Chaaya M, Prince M, Atweh S, El Asmar K, Karam G, et al. Dementia prevalence, care arrangement, and access to care in Lebanon: A pilot study. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.04.007>. [Epub ahead of print].
- [72] Crane PK, Trittschuh E, Mukherjee S, Saykin AJ, Sanders RE, Larson EB, et al. Incidence of cognitively defined late-onset Alzheimer's dementia subgroups from a prospective cohort study. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.04.011>. [Epub ahead of print].
- [73] Fereshtehnejad S-M, Garcia-Ptacek S, Religa D, Holmer J, Buhlin K, Eriksson M, et al. Dental care utilization in patients with different types of dementia: A longitudinal nationwide study of 58,037 individuals. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.05.004>. [Epub ahead of print].
- [74] Banks MP, Alonso A, Gottesman RF, Mosley TH, Selvin E, Pankow JS. Brain function and structure and risk for incident diabetes: The Atherosclerosis Risk in Communities Study. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.04.006>. [Epub ahead of print].
- [75] Perera G, Pedersen L, Ansel D, Alexander M, Arrighi HM, Avillach P, et al. Dementia prevalence and incidence in a federation of European Electronic Health Record databases: The European Medical Informatics Framework resource. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.06.2270>. [Epub ahead of print].
- [76] Lutsey PL, Misialek JR, Mosley TH, Gottesman RF, Punjabi NM, Shahar E, et al. Sleep characteristics and risk of dementia and Alzheimer's disease: The Atherosclerosis Risk in Communities

- Study. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.06.2269>. [Epub ahead of print].
- [77] Maestre GE, Mena LJ, Melgarejo JD, Aguirre-Acevedo DC, Pino-Ramirez G, Urribarri M, et al. Incidence of dementia in elderly Latin Americans: Results of the Maracaibo Aging Study. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.06.2636>. [Epub ahead of print].
- [78] Cerasuolo JO, Cipriano LE, Sposato LA, Kapral MK, Fang J, Gill SS, et al. Population-based stroke and dementia incidence trends: Age and sex variations. *Alzheimer's Dement* 2017;13:1081–8.
- [79] Bender AC, Austin AM, Grodstein F, Bynum JPW. Executive function, episodic memory, and Medicare expenditures. *Alzheimer's Dement* 2017;13:792–800.
- [80] Jonsson L, Lin P-J, Khachaturian AS. Special topic section on health economics and public policy of Alzheimer's disease. *Alzheimer's Dement* 2017;13:201–4.
- [81] Ton TGN, DeLeire T, May SG, Hou N, Tebeka MG, Chen E, et al. The financial burden and health care utilization patterns associated with amnesic mild cognitive impairment. *Alzheimer's Dement* 2017; 13:217–24.
- [82] Gustavsson A, Green C, Jones RW, Forstl H, Simsek D, de Reydet de Vulpillieres F, et al. Current issues and future research priorities for health economic modelling across the full continuum of Alzheimer's disease. *Alzheimer's Dement* 2017;13:312–21.
- [83] Sleeman KE, Perera G, Stewart R, Higginson IJ. Predictors of emergency department attendance by people with dementia in their last year of life: Retrospective cohort study using linked clinical and administrative data. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.06.2267>. [Epub ahead of print].
- [84] Larsen PA, Lutz MW, Hunnicutt KE, Mihovilovic M, Saunders AM, Yoder AD, et al. The Alu neurodegeneration hypothesis: A primate-specific mechanism for neuronal transcription noise, mitochondrial dysfunction, and manifestation of neurodegenerative disease. *Alzheimer's Dement* 2017;13:828–38.
- [85] Carrillo MC, Fillit H, Ganguli M, Knopman D, Shineman D, Snyder HM. Letter to the Editor re: Nexus of Cancer & Alzheimer's. *Alzheimer's Dement* 2017;13:722.
- [86] Louie RR. Comments on the "nexus" meeting report regarding dementia and cancer. *Alzheimer's Dement* 2017;13:720–1.
- [87] Calcium Hypothesis of Alzheimer's disease and brain aging: A framework for integrating new evidence into a comprehensive theory of pathogenesis. *Alzheimer's Dement* 2017;13:178–182.e17.
- [88] Overk C, Masliah E. Perspective on the calcium dyshomeostasis hypothesis in the pathogenesis of selective neuronal degeneration in animal models of Alzheimer's disease. *Alzheimer's Dement* 2017;13:183–5.
- [89] Linas R, Moreno H. Perspective on calcium and Alzheimer's disease. *Alzheimer's Dement* 2017;13:196–7.
- [90] Frain L, Swanson D, Cho K, Gagnon D, Lu KP, Betensky RA, et al. Association of cancer and Alzheimer's disease risk in a national cohort of veterans. *Alzheimer's Dement* 2017; <https://doi.org/10.1016/j.jalz.2017.04.012>. [Epub ahead of print].

<https://doi.org/10.1016/j.dadm.2017.11.004>